1. FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. (12th June 2018) Authors: Werth, V.P.; Hejazi, E.; Pena, S.M.; Haber, J.S.; Okawa, J.; Feng, R.; Gabre, K.; Concha, J.S.; Cornwall, C.; Dgetluck, N.; Constantine, S.; White, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001. (12th June 2018) Authors: Werth, V.P.; Patel, B.; Concha, J.S.; Okawa, J.; Pearson, D.; Hejazi, E.; Feng, R.; Cornwall, C.; Dgetluck, N.; Constantine, S.; Aggarwal, A.; White, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗